Each uncoated tablet contains:
Telmisartan IP 40 mg
Hydrochlorothiazide IP 12.5 mg
Telmesartan is used in combination with hydrochlorthiazide to treat hypertension and reduce the risk of stroke in patients with left ventricular hypertrophy and hypertension, kidney problems .
Used in the management of edema associated with congestive heart failure
- In hypertension
Telmesartan is the angiotensin 2 receptor blocker to treat hypertension . It is used to treat diabetic nephropathy in patients with type 2 diabetes mellitus. Telmesartan improves the carbohydrate as well as lipid metabolism.
hydrochlorthiazide is the thiazide diuretic . It treats edema and hypertension.
Mechanism of action
hydrochlorthiazide prevents the reabsorption of the sodium and water from the distal convoluted tubule by inhibiting the sodium chloride symporter and allowing the water excretion via urine .
Telmesartan competitively blocks the AT1 receptor present in the smooth muscles and adrenal gland from binding with angiotensin 2 ( vasoconstrictor) therefore prevent the synthesis of aldosterone and angiotensin 2 mediated effect i.e relaxation of vascular smooth muscles and lowers the blood pressure.
It is orally absorbed and its bioavailability decreases with administration of the food.
Protein binding -
It is highly protein bound upto 99.5%, mainly to albumin
It undergoes glucuronide conjugtion.
It is excreted via urine
It is orally absorbed
Protein binding -
It is about 40 to 60% protein bound.
Hydrochlorthiazide is metabolized in the liver.
It is excreted unchanged in the urine.
- It is contraindicated in people who are unable to pass urine
- It is contraindicated in people who are consuming aliskiren medication
It is stored at room temperature